EANM presentations to showcase new data and developments from Telix’s Theranostics pipeline

MELBOURNEAustralia and LIEGE, Belgium, October 10, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, The Company) today announces its attendance at the European Association of Nuclear Medicine (EANM) Annual Meeting to be held in Barcelona of October 15-19, 2022.

dr. Colin HaywardTelix Chief Medical Officer said: “Telix is ​​delighted to have such a presence at EANM’22, which is being held in person for the first time since 2019. Our sponsored symposium provides insight into advances in imaging, surgery and management of patients for the field of genitourinary oncology. The congress program also includes updates on a wide variety of Telix-sponsored and investigator-initiated studies and research collaborations, including preliminary readings of data, in particular identifying carbonic anhydrase IX (CAIX) as a therapeutic target beyond kidney cancer. The breadth of our innovative theranostics pipeline is proof of our commitment and progress towards the advancement of nuclear medicine in a range of indications.

The details of the presentation of the EANM are as follows:

Sponsored Symposium: Shifting Perspectives in Genito-uriary Oncology through Nuclear Medicine

  • President: Teacher Wolfgang Fendler – Vice President, Clinic for Nuclear Medicine, University Hospital Essen, Essen, Germany.
  • PET-ligand PSMA imaging: current situation and impact on patient care.

-Teacher Wolfgang Fendler.

  • Interventional nuclear medicine: focus on radio-guided surgery in urological cancers.

-Professor Jochen Walz – Head of the Urology Department at the Cancer Center of the Paoli-Calmettes Institute, Marseille, France.

  • Redefining the care of patients with kidney cancer.

-Doctor Stijn Muselaers – Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands.

  • Establish radioligand imaging and therapy in hospital practice.

-Professor Zéna Wimana – Head of Radiopharmacy, Nuclear Medicine Department, Jules Bordet Institute, Brussels, Belgium.

  • Date and hour : Sunday,October 16, 2022, 1:15 p.m. – 2:45 p.m. CET.

Oral presentations:

  1. Preclinical evaluation of targeted radiotherapy combined with immune checkpoint inhibition.
    Highest Rated Oral Presentation (TROP).
    Date and hour : Sunday, October 16, 20223:50 p.m. – 4:00 p.m. CET.
    Presenter: Simone Kleinendorst (University Medical Center of Radboud).
    Submission number: OP-170.
  2. PROSTACT TARGET: oligometastatic prostate cancer treated with external radiotherapy and radioligand Theranostics.
    Highest Rated Oral Presentation (TROP).
    Date and hour : Monday, October 17, 202210:55 a.m. – 11:05 a.m. CET.
    Presenter: Neel Patel (Telix Pharmaceuticals).
    Submission number: OP-386.
  3. Preliminary Results of a Prospective Pilot Study Evaluating the Imaging Performance of Zirconium-89 Labeled Girentuximab PET-CT in Patients with Triple Negative Metastatic Breast Cancer (OPALESCENCE).
    Highest Rated Oral Presentation (TROP).
    Date and hour : Monday, October 17, 20223:40 p.m. – 3:50 p.m. CET.
    Presenter: Caroline Rousseau (Western Cancer Institute).
    Submission number: OP-454.
  4. An automated [89Zr]ZrCl4-based platform for radiolabeling of [89Zr]Zr-DFOsq agents on the iPhase MultiSyn module.
    Highest Rated Oral Presentation (TROP).
    Date and hour : Tuesday, October 18, 20225:45 p.m. – 5:55 p.m. CET.
    Presenter: Catherine Fitzgerald (University of Melbourne).
    Submission number: OP-741.
  5. PSMA PET/CT detected prostate cancer metastasis in patient with negative mp-MRI and prostate biopsy.
    Date and hour : Sunday, October 16, 202209:14 – 09:18 CET.
    Presenter: Luigia Vetrone (University of Bologna).
    Submission number: OP-031.

Poster presentations:

  1. Preliminary results of a clinical feasibility study with intravesically instilled 89Zr-labeled Girentuximab in patients with non-muscle-invasive bladder cancer for future alpha-immunotherapy (RELEVANCE).
    Presenter: Caroline Rousseau (Western Cancer Institute).
    Submission number: EP-172.
  2. Clinical translation of chimeric antibody DAB4 (chDAB4) targeting dead cancer cells as a theranostic tool to diagnose cancer treatment responses.
    Presenter: Alex Staudacher (University of Adelaide).
    Submission number: EP-103.

Register here for EANM’22: https://eanm22.eanm.org/

[1] ASX disclosure December 20, 2021.
[2] ASX disclosure November 2, 2021.
[3] ASX Disclosure December 16, 2020.

About Telix Pharmaceuticals Limited

Telix is ​​a biopharmaceutical company specializing in the development and marketing of diagnostic and therapeutic radiopharmaceuticals. Telix is ​​headquartered in Melbourne, Australia with international operations in United States, Europe (Belgium and Swiss), and Japan. Telix is ​​developing a clinical-stage product portfolio that aims to address significant unmet medical needs in oncology and rare diseases. Telix is ​​listed on the Australian Securities Exchange (ASX: TLX). For more information, visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and LinkedIn.

Telix’s flagship product, gallium-68 (68Ga) gozetotide (also called 68Ga PSMA-11) injection, has been approved by the United States Food and Drug Administration (FDA),[1] and by the Australian Therapeutic Goods Administration (TGA).[2] Telix is ​​also pursuing a marketing authorization application for this experimental candidate in Canada.[3]

Telix Investor Relations

Ms Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
E-mail: [email protected]

Publication of this announcement has been authorized by the Disclosure Committee of Telix Pharmaceuticals Limited.

Legal Notice

This announcement is not intended to be a promotion or advertisement to any healthcare professional or other audience in any country in the world (including Australia, United States and the UK). This announcement may include forward-looking statements relating to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed. or implied by these forward-looking statements. research statements. Forward-looking statements are based on the Company’s good faith assumptions about financial, market, regulatory and other risks and considerations that exist and affect the Company’s business and operations in the future, and there can be no assurance that either of the assumptions prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements regarding: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development of Telix; Telix’s ability to advance product candidates, enroll in and complete clinical studies, including multinational clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialization of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital needs; the financial performance of Telix; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. The actual results, performance or achievements of Telix may differ materially from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. You should read this announcement together with our risk factors, as disclosed in our latest reports filed with the ASX or on our website.

To the fullest extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions.

The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.

Logo – https://mma.prnewswire.com/media/1775408/Telix_Logo.jpg

SOURCE Telix Pharmaceuticals Limited

Comments are closed.